[Click eStock] "Celltrion, Improving Profitability with High-Margin Biosimilars"

Kiwoom Securities forecasted on the 19th that Celltrion will improve its profitability thanks to increased sales of high-margin biosimilars.

Advertising image of Celltrion's autoimmune disease treatment 'Jimpentra' in US media [Photo by Celltrion]

Huh Hyemin, an analyst at Kiwoom Securities, stated, "The proportion of sales from Celltrion's follow-up biosimilar products increased from 27% in Q2 this year to 39% in Q3," adding, "Profitability is expected to improve as the share of high-margin products gradually increases going forward."

Analyst Huh evaluated, "Expectations for the autoimmune disease treatment ‘Jimpentra’ have lowered," and "We have revised down the sales forecast for Jimpentra to 50 billion KRW this year and 225 billion KRW next year."

However, he noted, "In Europe, the subcutaneous injection form (SC) of Remsima surpassed quarterly sales of 100 billion KRW five years after its launch and achieved 170.9 billion KRW in Q3 this year," adding, "If the growth of Remsima SC continues, favorable expectations for Jimpentra may be formed."

He added, "Although we lowered the target stock price to 240,000 KRW due to the reduced expected performance of Jimpentra," he also said, "The stock price has fallen about 18% since the end of July, reducing valuation pressure, and the stock price is expected to gradually recover with improved profitability."

This content was produced with the assistance of AI translation services.